Treatment of Renal Vein Thrombosis in Venous Thromboembolism with Antiphospholipid Syndrome

Clinical Scenario

This protocol covers renal vein thrombosis presenting in the context of venous thromboembolism (VTE) in patients with antiphospholipid syndrome — an autoimmune condition that substantially influences anticoagulation management and requires departure from standard VTE pathways.

Treatment Approach

Anticoagulation selection in this population is guided by the underlying syndrome and the patient's specific antibody profile. One class of oral anticoagulant is recommended over others in this setting — the full protocol outlines the selection rationale and the clinical factors that determine the appropriate choice.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3949/ccjm.91a.22090

Current recommendations favor the use of vitamin K antagonists over DOACs for VTE treatment in these patients, especially those with triple-positive antiphospholipid syndrome (presence of lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein 1 antibodies).

View source ↗